

## RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 20.04.2021)

*Milan, 19<sup>th</sup> March 2021 – Please be informed that the Directors' Report relating to item no. 3 (Proposal to approve the 2021-2023 Stock Option Plan, including the relative Information Memorandum drawn up pursuant to art. 84-bis of the Regulation approved by Consob resolution no. 11971 of 14 may 1999, as subsequently amended and integrated) and the Directors' Report relating to item no. 4 (Proposal to authorise the purchase and disposal of treasury stock) of the agenda of the Ordinary Shareholders' meeting called for 20<sup>th</sup> April 2021 – both approved by the Board of Directors on 18<sup>th</sup> March 2021 – are available to the public, as of today, at the Company's registered office and published on the Company's website ([www.recordati.it](http://www.recordati.it), section Investors, Shareholders' Meeting) and on the '1INFO' storage mechanism ([www.1info.it](http://www.1info.it)).*

*Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2020 was € 1,448.9 million, operating income was € 469.0 million and net income was € 355.0 million.*

For further information:

Recordati website: [www.recordati.com](http://www.recordati.com)

Investor Relations

Federica De Medici  
(39) 02 48787146  
e-mail: [investorelations@recordati.it](mailto:investorelations@recordati.it)

Media Relations

Studio Noris Morano  
(39) 02 76004736, (39) 02 76004745  
e-mail: [norismorano@studionorismorano.com](mailto:norismorano@studionorismorano.com)

### RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office

Via Matteo Civitali, 1  
20148 Milano, Italy  
Ph. (39) 02 487871  
Fax (39) 02 40073747  
[www.recordati.com](http://www.recordati.com)

Share Capital € 26.140.644,50 fully paid-up  
Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150  
Tax Code/VAT No. 00748210150  
Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.à.r.l